Results of the phase B of the IMMhance study show that more than 80% of patients continuously treated with the IL-23 inhibitor risankizumab reach complete or almost complete clearance of their psoriasis after two years .
The IMMhance study consisted of 2 phases: results from the first phase were previously reported, and showed that after 16 weeks of treatment, the selective IL-23 inhibitor risankizumab (n=407) met the co-primary endpoints Psoriasis Area and Severity Index (PASI) improvement by 90% and complete or almost complete clearance of skin lesions according to physicians global assessment (sPGA 0/1) vs placebo (n=100) (P<0.001). The second phase (week 28 through week 104) of this trial evaluated the efficacy and safety of continuous therapy with risankizumab vs randomised withdrawal, as well as re-treatment.
Patients who achieved sPGA 0/1 at wee...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Surgical management of melanoma Next Article
New targets and biologics for cutaneous lupus erythematosus »